Replies to post #358 on Oxford BioMedica PLC (OXBDF)

[georgejjl]

I believe that Oxford BioMedica is working on two pathways for using CART therapy to treat solid tumors.

One pathway is CAR T 5T4 which I believe that Oxford BioMedica is working without Novartis. See page 10 at the following link.

http://www.oxfordbiomedica.co.uk/uploads/corporate-presentation/oxb-jefferies-conf-ny-june16-csc.pdf

The other pathway for using CART to treat solid tumors Oxford BioMedica is working with and under the direction of Novartis and the University of Pennsylvania.

Novartis (CTL-019 and other undisclosed CAR-T programme) see page 7 at the link.

That undisclosed CAR-T programme is I believe based on the "Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells"

Good luck and GOD bless,

George